|
|
Volumn 35, Issue 1, 2011, Pages 3-7
|
|
Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ARSENIC TRIOXIDE;
RETINOIC ACID;
CANCER CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER SURVIVAL;
EDITORIAL;
FOLLOW UP;
HEALTH CARE COST;
HUMAN;
LEUKEMIA RELAPSE;
LEUKEMIA REMISSION;
MINIMAL RESIDUAL DISEASE;
PATIENT MONITORING;
PRIORITY JOURNAL;
PROGNOSIS;
PROMYELOCYTIC LEUKEMIA;
QUALITY ADJUSTED LIFE YEAR;
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;
SALVAGE THERAPY;
UNSPECIFIED SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
BONE MARROW TRANSPLANTATION;
HUMANS;
LEUKEMIA, PROMYELOCYTIC, ACUTE;
MONITORING, PHYSIOLOGIC;
NEOPLASM, RESIDUAL;
|
|
EID: 78650177461
PISSN: 01452126
EISSN: None
Source Type: Journal
DOI: 10.1016/j.leukres.2010.06.018 Document Type: Editorial |
|
Times cited : (15)
|
|
References (0)
|
